CRISPR System Identifies New Target to Treat Leukemia

by Megha Ramaviswanathan on  March 10, 2018 at 2:02 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

A new research by scientists at Cold Spring Harbor Laboratory reveals that chemicals which are used to target certain enzymes can be developed into drugs that further provide an opportunity to develop therapies against some aggressive leukemias. The findings of the study are published in the journal Molecular Cell.
CRISPR System Identifies New Target to Treat Leukemia
CRISPR System Identifies New Target to Treat Leukemia

MEF2C is a transcription factor--a regulatory protein that helps control the activity of certain genes. Its overactivity is implicated in about 15% of cases of acute myeloid leukemia (AML), a rapidly progressing cancer of the blood and bone marrow that is often fatal.

CSHL Associate Professor Christopher Vakoc, M.D., Ph.D., and colleagues now report that they can stop the growth of MEF2C-driven AML cells by blocking either of two target enzymes, known as LKB1 and salt-inducible kinase. The chemicals that the team used to interfere with the enzymes are small molecules that have the potential to be developed into drugs, Vakoc says.

The discovery is the result of a broad search for potential therapeutic strategies against AML that began several years ago in Vakoc's lab. In 2013, his team devised a system based on CRISPR gene editing tools that they used to screen large numbers of genes, seeking to discover their impact on cancer cell survival. "We just let the cancer cells tell us what types of genes they need in order to grow," Vakoc says.

Led by Yusuke Tarumoto, a postdoctoral researcher in Vakoc's lab, the team has now deployed that technology against AML. Their screens revealed that LKB1 and salt-inducible kinase are critical for the survival of certain AML cells. The enzymes had not previously been linked to AML, but with further experiments, the team learned that both help control the MEF2C transcription factor, which is a known cancer promoter.

"At the end of project, we realized we'd had actually discovered a way to control a transcription factor," says Vakoc. That's exciting, he says, because while most leukemias are thought to be caused by wayward transcription factors, such proteins are among the most challenging to target with drugs.

The chemicals the team used to switch off LKB1 and salt-inducible kinase in their lab-grown cancer cells are not suitable as therapeutic compounds, but Vakoc is optimistic that it will be possible to develop drugs that target these enzymes. Animal experiments are already under way in his lab to begin to investigate the strategy as a potential treatment approach.



Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

Recommended Reading

More News on:

Leukemia Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Multiple Myeloma Bone Marrow Transplantation Hairy Cell Leukemia CRISPR 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive